Easing Discomfort in Primary Dysmenorrhea and Menstrual Pain

This medication is primarily used in the management of Primary Dysmenorrhea and is applied in addressing symptoms related to physical discomfort, such as the cramping pain that may accompany the menstrual cycle. It is used in conditions involving episodic or fluctuating manifestations. This application contributes to easing the overall symptom load during periods of heightened symptoms and may assist with maintaining functional stability during difficult episodes.

---

Relief from Acute Pain, Inflammation, and Fever

The medication is commonly used across conditions presenting with acute episodes to help manage symptom clusters: mild to moderate pain, localized inflammation, and systemic fever. It is applied in clinical settings that involve acute or unstable symptom patterns, such as musculoskeletal aches. It is used to help with symptom clusters that may become intense or disruptive, providing supportive relief that helps ease the overall symptom load and may assist with maintaining functional stability. It is applied when these conditions produce significant symptomatic burden and when additional management of discomfort is required, helping to maintain stability when symptoms are more noticeable.

---

Focus: Symptomatic Support for Acute Manifestations

Suprazen Forte is generally used to provide short-term symptomatic assistance in conditions characterized by periods of heightened symptoms, particularly recurrent or acute episodes of pain and inflammation.

Regulatory References

1. NIH DailyMed Official Label for Mefenamic Acid

Suprazen Forte (Mefenamic Acid) is an anti-inflammatory medicine with strict rules governing who can and cannot use it, based on official regulatory documents.

Contraindicated Populations (Must Not Use)

Use is absolutely contraindicated in patients with a history of hypersensitivity or allergic-type reactions (like asthma or hives) to aspirin or other NSAIDs. It must not be taken by patients with active gastrointestinal ulceration, chronic GI inflammation, a history of GI bleeding, or those with severe heart failure (NYHA Class II-IV), severe hepatic failure, or severe renal failure.

It is also contraindicated for treating pain immediately before or after Coronary Artery Bypass Graft (CABG) surgery.

Restricted and Special Consideration Groups

• Age: It is not recommended for children under 14 years of age. Use in elderly patients requires caution due to an increased risk of serious gastrointestinal events and renal impairment.
• Pregnancy/Lactation: It is contraindicated in the last trimester of pregnancy (from 30 weeks gestation) and should not be taken by nursing mothers.
• Existing Conditions: Caution and close monitoring are required for patients with pre-existing conditions like uncontrolled hypertension, mild to moderate heart, liver, or renal impairment, or those who are attempting to conceive.

Interactions with other medicines and products

This section details documented interaction patterns for Mefenamic Acid based on authoritative government regulatory sources.

Element	Regulatory Statement
Medicinal product categories with documented interactions:	Oral Anticoagulants, Non-Aspirin NSAIDs, Antihypertensives (e.g., ACE Inhibitors, Diuretics), SSRIs, Lithium, Methotrexate, Antacids.
Mechanistic basis of interactions (only if stated in label):	Pharmacokinetic interaction (metabolism via CYP2C9); Pharmacodynamic interaction (additive bleeding risk, reduced therapeutic efficacy).
Interaction-related restrictions:	Co-administration with other systemic non-aspirin NSAIDs (including COX-2 inhibitors) should be avoided.

---

Official interaction statements:

• The drug enhances the effects of Oral Anticoagulants (e.g., Warfarin, Apixaban) and anti-platelet agents, increasing the documented risk of both gastrointestinal and non-gastrointestinal bleeding.
• The anti-platelet effect of low-dose Aspirin may be interfered with, reducing its prophylactic efficacy when co-administered.
• Co-administration with Lithium causes a reduction in renal clearance, resulting in the elevation of plasma lithium levels and toxicity risk.
• The antihypertensive effect of ACE Inhibitors, Angiotensin II Receptor Antagonists, and Diuretics is reduced.
• Antacids containing Magnesium Hydroxide significantly increase the rate and extent of Mefenamic Acid absorption.
• Alcohol consumption may increase the documented risk of gastrointestinal bleeding, ulceration, and perforation.
• Mefenamic Acid is primarily metabolized by the enzyme CYP2C9; poor CYP2C9 metabolisers may experience abnormally high plasma levels.

---

Connection to the overall interaction profile

Regulatory documents define the product’s interaction profile based on pharmacodynamic risk reinforcement and pharmacokinetic modification. This establishes specific constraints, such as avoiding other systemic NSAIDs and mandates caution for combinations with anticoagulants and drugs affecting renal clearance like Lithium.

Dual Interruption of Prostaglandin Signaling

The active component, Mefenamic Acid, operates through a dual approach. Primarily, it acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes ( COX-1 and COX-2), which catalyze the synthesis of lipid mediators called prostaglandins ( PGE2) from the Arachidonic Acid Cascade. Secondarily, the drug functions as an antagonist, directly blocking the E-type Prostanoid (EP) Receptors that these mediators use to activate cells. This combined inhibition of production and antagonism of reception rapidly limits the impact of these signaling molecules, resulting in reduced sensitization of peripheral nociceptors and suppressed fluid exudation in local tissues.

Central Modulation of Thermoregulation

This mechanism extends to the hypothalamus, the brain region critical for central thermoregulation. By preventing the excessive synthesis of PGE2 in the central nervous system, the drug facilitates the resetting of the body’s thermoregulatory set-point. This physiological adjustment supports the dissipation of excess heat, contributing to the mechanism's antipyretic profile.

Mechanistic Limitations

The non-selective nature of the enzyme inhibition inherently reduces prostaglandins generated by the constitutive COX-1 isoform, which are vital for maintaining protective physiological functions, such as the integrity of the gastrointestinal mucosal barrier and renal blood flow autoregulation.

Administration Guidelines

Suprazen Forte is used for oral administration through dosage forms such as 250 mg capsules or 500 mg film-coated tablets, depending on the region.

Dosing and Frequency

The standard adult regimen for acute conditions in patients 14 years of age and older begins with an initial 500 mg dose. This initial dose is followed by a maintenance dose of 250 mg taken every six hours as needed. In some protocols, a regimen of 500 mg three times daily is utilized. The daily dose must not exceed the maximum amount specified in the prescribing instructions.

Administration Context and Duration

The medicine is taken with food, milk, or a full glass of water (8–12 oz) to ensure proper intake conditions. For primary dysmenorrhea, treatment typically begins at the onset of menstrual bleeding and associated pain. Use is limited to short-term courses; duration is generally not to exceed two to three days for dysmenorrhea and a maximum of seven days for acute pain.

Procedural Requirements

The established approach involves the use of the lowest effective dose for the shortest possible duration. Patients are instructed not to double the next dose if a scheduled administration is missed. Dose adjustments may be required in specific populations, such as older adults or those with hepatic impairment, reflecting the need for modification in those groups. These instructions collectively define the standardized approach to using the medicine.

Research Evidence / Overview of Studies for Suprazen Forte (Mefenamic Acid)

This overview describes the research landscape for Suprazen Forte, focusing on the types of studies regulators rely on, the outcomes these studies examined, and the areas where research remains limited or uncertain. This information is purely descriptive and is not a substitute for clinical guidance.

---

Evidence for use in Primary Dysmenorrhea (Menstrual Pain)

Research exploring Mefenamic Acid was studied for conditions characterized by fluctuating or episodic manifestations, such as primary dysmenorrhea, primarily consists of randomized controlled trials (RCTs) and subsequent systematic reviews. These studies were designed to compare the medication against a placebo or against other analgesic medications. The research examined patient-reported outcomes describing perceived discomfort, specifically focusing on how symptoms change over time during the menstrual cycle.

Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to outcomes monitoring physiological strain or stress. The body of evidence for this use is supported by a classification of high-level evidence, which reflects the consistency seen across multiple short-term RCTs. The results apply only to the populations studied, which were often healthy, younger adult females.

---

Evidence for use in Acute Mild to Moderate Pain

Mefenamic Acid was studied for conditions involving periods of heightened symptoms (acute mild to moderate pain). The evidence structure is based on short-term randomized controlled trials and systematic reviews that combine findings from these very short-term studies. Research examined temporary physiological imbalance using specific models, such as pain experienced after dental procedures or minor surgery.

The studies explored outcomes describing episodic or acute changes, such as the patient's report of pain relief over a defined time interval. The evidence structure for Mefenamic Acid in acute symptoms provides context for the broader evidence landscape for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).

---

Scientific Uncertainty and Research Gaps

Key limitations in the evidence landscape stem from the fact that follow-up durations were limited across many core trials, restricting understanding of long-term patterns. There is limited information available for the use of Mefenamic Acid in older adults or in individuals with significant underlying medical conditions. Detailed evidence focusing on children under the age of 14 is limited or non-existent for the conditions that were studied.

Key Studies & References Mefenamic Acid: DailyMed Official Label (NIH National Library of Medicine)

Common questions about Suprazen Forte (FAQ)

Q: What is Suprazen Forte primarily used to treat?

Official regulatory documents indicate that Suprazen Forte (Mefenamic Acid) is primarily indicated for the relief of mild to moderate pain in patients 14 years of age and older. It is also indicated for the treatment of primary dysmenorrhea (menstrual pain). Its use is generally limited to short-term courses, as stated in the product information, and typically does not exceed one week.

Q: How quickly can patients typically expect to notice the effects of Suprazen Forte?

Studies and official information indicate that the active ingredient is rapidly absorbed after oral administration. Peak plasma levels of the active ingredient are typically reached between two to four hours after administration.

Q: How long does the primary action of a single dose of Suprazen Forte last in the body?

According to the official product information, the elimination half-life of Mefenamic Acid is approximately two hours. The half-life refers to the time it takes for the amount of medication in the body to decrease by half.

Q: What are the most commonly reported side effects of Suprazen Forte?

Regulatory documents state that some of the more commonly reported side effects include gastrointestinal issues such as diarrhea, abdominal pain, nausea, and vomiting. Dizziness is also listed among the commonly reported effects.

Q: Is it common to experience dizziness or drowsiness while taking Suprazen Forte?

Yes, official regulatory labeling lists both dizziness and drowsiness (somnolence) among the side effects that have been reported. These central nervous system effects are categorized in the product information as either common or less common.

Q: What kind of side effects are generally classified as serious for this medicine?

Official warnings and precautions highlight the potential for serious adverse events. These include severe gastrointestinal damage (bleeding, ulcers, or perforation), increased risk of cardiovascular thrombotic events (such as heart attack or stroke), and severe allergic or skin reactions.

Q: Does Suprazen Forte have a Black Box Warning or similar high-level safety alert?

Yes, the official U.S. Food and Drug Administration (FDA) labeling includes a Boxed Warning. This high-level safety alert concerns the potential for serious, sometimes fatal, cardiovascular thrombotic events and serious gastrointestinal bleeding and perforation.

Q: What should be done if a common side effect, such as nausea, persists after starting the medicine?

General guidance from regulatory patient information advises that if any side effects, even common ones, persist or begin to worsen, it is advised to contact a healthcare provider for further evaluation and guidance.

Q: Is a generic version of Suprazen Forte currently available?

The active ingredient in Suprazen Forte, Mefenamic Acid, is available as a generic medication. Generic products are available, which contain the same active ingredient.

Q: Does Suprazen Forte contain the same active ingredient as any other well-known drug?

The active ingredient, Mefenamic Acid, is the same ingredient found in other NSAID products that were previously or currently marketed under different brand names, such as Ponstel (which is now mostly available generically).

Q: Are there different conditions that Suprazen Forte is approved to treat?

Official product information indicates that Mefenamic Acid has approved indications for both primary dysmenorrhea and acute mild to moderate pain.

Q: What are the official safety warnings or precautions listed for Suprazen Forte?

Official documents contain numerous warnings, most notably regarding the risk of gastrointestinal bleeding and cardiovascular events. These documents emphasize that the medicine is associated with risks that require caution in certain patient groups and mandate the use of the lowest effective dose for the shortest duration possible.

Q: How are severe allergic reactions to Suprazen Forte officially described?

The official product information lists a history of allergic-type reactions (such as asthma, hives, or swelling) to aspirin or other NSAIDs as an absolute contraindication. This highlights the serious and potentially life-threatening nature of a potential hypersensitivity reaction.

Q: Is there a known risk of dependence or withdrawal associated with Suprazen Forte?

Mefenamic Acid is a Nonsteroidal Anti-Inflammatory Drug (NSAID). Official regulatory information does not indicate a risk of dependence or withdrawal that is typically associated with opioid pain medications or certain psychiatric drugs.

Q: Are there specific foods or beverages that should be avoided when taking Suprazen Forte?

The official label specifically warns that alcohol consumption may increase the documented risk of serious gastrointestinal issues, including bleeding and ulcers. The medicine is generally advised to be taken with food, milk, or a full glass of water to ensure proper intake conditions.

Q: What over-the-counter (OTC) medicines are known to interact with Suprazen Forte?

Official interaction information notes that the medicine can interact with several types of drugs that may be available OTC. For instance, co-administration with other systemic non-aspirin NSAIDs is generally advised to be avoided, and some antacids can significantly increase the absorption of Mefenamic Acid.

Q: What are the main findings of the pivotal clinical trials for Suprazen Forte?

The research evidence relies on randomized controlled trials (RCTs) that focused on short-term relief. These studies examined patient-reported outcomes, describing changes in perceived discomfort and pain relief over defined time intervals for conditions like menstrual pain and acute mild to moderate pain.

Q: Is there public information available about any ongoing clinical studies or research related to Suprazen Forte?

While regulatory documents detail the research that led to approval, they note that follow-up durations were often limited, and information is sparse for certain groups, such as older adults. Information on currently ongoing clinical studies is generally managed through public clinical trial registries and is not typically detailed in the official drug labeling.

Q: Is there information available on how Suprazen Forte is processed and removed from the body?

Official documents confirm that Mefenamic Acid is primarily broken down in the liver by the enzyme CYP2C9. It is also noted that co-administration with certain drugs, such as Lithium, can affect how the body removes the drug by potentially reducing renal clearance.

How to Store and Dispose of Suprazen Forte?

The official storage guidelines for Suprazen Forte (Mefenamic Acid) are intended to maintain product integrity and safety.

---

Storage Requirements

The medicine must be stored at Controlled Room Temperature, which must not exceed 30°C.

• Protection: The product must be protected from light, excess heat, and moisture; therefore, avoid storage in areas like the bathroom.
• Container: The container must be kept tightly closed to maintain stability.
• Child Safety: It is mandatory to keep this medication out of the reach of children at all times.

---

Disposal Instructions

Discard unused or expired medication using an authorized drug take-back program whenever possible. If a program is unavailable, mix the medicine with an undesirable substance (such as used coffee grounds), seal it in a container, and place it in the household trash. Do not flush Suprazen Forte down a sink or toilet.